| HOME >> MEDICINE >> TECHNOLOGY |
This superiority was evident after the first week of treatment and was maintained at all time points until week 16 (p<0.05). At the primary endpoint at 24 weeks, Cipralex(R) was at least as effective as duloxetine (p=0.055)(1).
At the end of the secondary pre-defined endpoint at week 8, patients taking Cipralex(R) demonstrated significantly greater improvement than patients taking duloxetine as determined by MADRS and other predefined secondary endpoints such as the Clinical Global Impression - Improvement (CGI-I) and the Sheehan Disability Scale (SDS) scores(1).
Significantly more people taking duloxetine withdrew from the study compared to those taking Cipralex(R) (17% vs 9% respectively, p<0.05)(1).
A post-hoc analysis of the present study revealed a significant advantage for Cipralex(R) (68.8% early responders) versus duloxetine (54.8%)(1).
About depression
Depression is a very common, debilitating illness affecting around 121 million people worldwide(8). The symptoms of depression can be chronic or recurrent, and impact patients both mentally and physically. Depression has a significant impact on patient quality of life and imposes a considerable burden on society, yet it is still underrecognised and undertreated with less than 25 percent of those affected having access to effective treatment(8).
Symptoms include feelings of hopelessness, sadness, guilt, loss of interest in activities, decreased energy, poor concentration, persistent physical symptoms such as headache and digestive disorders, and in more severe cases, suicidal thoughts and suicide attempts(9).
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company
engaged in the research and development, production, marketing and
sale of drugs for the treatment of psychiatric and neurological
disorders. In 2006, the company's revenue was DKK 9.2 billion
(approximately EUR 1.2 bill
'"/>